AffiliationDepartment of Histopathology, Christie Hospital NHS Trust, Manchester, UK.
MetadataShow full item record
AbstractVS38 was originally described as a marker of neoplastic and non-neoplastic plasma cells. We recently described its immunoreactivity with melanocytic lesion. The aim of the present study was to investigate the reactivity of VS38 with various neuroendocrine tumours. Using paraffin sections of routinely processed archival tissue we found that 72% of 50 neuroendocrine tumours tested showed immunohistochemical positivity for VS38. A wide spectrum of neuroendocrine tumours were positive. Use of a panel of markers and awareness of the lack of specificity of VS38 will avoid misdiagnosis, particularly when neuroendocrine tumours and other lesions which react immunohistochemically with this antibody are located at unusual sites and exhibit plasmacytoid features.
CitationVS38 immunostaining in neuroendocrine tumours. 1997, 30 (3):256-9 Histopathology
- VS38 immunostaining in melanocytic lesions.
- Authors: Shanks JH, Banerjee SS
- Issue date: 1996 Mar
- VS38: a new monoclonal antibody for detecting plasma cell differentiation in routine sections.
- Authors: Turley H, Jones M, Erber W, Mayne K, de Waele M, Gatter K
- Issue date: 1994 May
- Shared tumor antigens in colorectal carcinoma and neuroendocrine tumors.
- Authors: Tobi M, Darmon E, Rozen P, Baratz M, Lundqvist M, Oberg K, Thomas P, Esteban J, Hefta S, Paxton R, Shively J
- Issue date: 1998
- Immunohistochemistry of malignant lymphomas. Advantages and limitations of the new monoclonal antibodies working in paraffin sections.
- Authors: Pileri S, Falini B, Sabattini E, Bigerna B, Gherlinzoni F, Tazzari PL
- Issue date: 1991 May-Jun
- The plasma cell associated antigen detectable by antibody VS38 is the p63 rough endoplasmic reticulum protein.
- Authors: Banham AH, Turley H, Pulford K, Gatter K, Mason DY
- Issue date: 1997 Jun